PRAXIS PRECISION MEDICINES

praxis-precision-medicines-logo

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain.
#SimilarOrganizations #People #Financial #Website #More

PRAXIS PRECISION MEDICINES

Social Links:

linkedin

Linkedin

twitter

Twitter

facebook

Facebook

x

X

Industry:
Alternative Medicine Biotechnology Health Care Medical Precision Medicine

Founded:
2015-09-22

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.praxismedicines.com

Total Employee:
51+

Status:
Active

Contact:
(617)949-2220

Total Funding:
573.12 M USD

Technology used in webpage:
HSTS DNSSEC Content Delivery Network Amazon LetsEncrypt DoubleClick.Net ReCAPTCHA JsDelivr Cloudflare JS Amazon Virginia Region


Similar Organizations

aro-biotherapeutics-logo

Aro Biotherapeutics

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

cabaletta-bio-logo

Cabaletta Bio

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

coriell-life-sciences-logo

Coriell Life Sciences

Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

interline-therapeutics-logo

Interline Therapeutics

Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.

thrive-earlier-detection-logo

Thrive Earlier Detection

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

verismo-therapeutics-logo

Verismo Therapeutics

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.


Current Advisors List

alfred-w-sandrock-jr_image

Alfred W. Sandrock Jr. Board Member @ Praxis Precision Medicines
Board_member

william-young_image

William Young Board Member @ Praxis Precision Medicines
Board_member

Current Employees Featured

alex-nemiroff_image

Alex Nemiroff
Alex Nemiroff General Counsel @ Praxis Precision Medicines
General Counsel
2020-06-01

megan-sniecinski_image

Megan Sniecinski
Megan Sniecinski Chief Business Officer @ Praxis Precision Medicines
Chief Business Officer
2021-12-01

marcio-souza_image

Marcio Souza
Marcio Souza President and CEO @ Praxis Precision Medicines
President and CEO
2020-04-01

david-goldstein_image

David Goldstein
David Goldstein Founder @ Praxis Precision Medicines
Founder
2019-01-01

lisa-huang_image

Lisa Huang
Lisa Huang Director of Corporate Development @ Praxis Precision Medicines
Director of Corporate Development

kelly-mccue_image

Kelly McCue
Kelly McCue Chief People Officer @ Praxis Precision Medicines
Chief People Officer
2021-01-01

alyssa-wyant_image

Alyssa Wyant
Alyssa Wyant Chief Regulatory and Quality Officer @ Praxis Precision Medicines
Chief Regulatory and Quality Officer
2021-12-01

elliot-ehrich_image

Elliot Ehrich
Elliot Ehrich Scientific and Clinical Advisory Board Member @ Praxis Precision Medicines
Scientific and Clinical Advisory Board Member
2018-11-01

nicholas-galakatos_image

Nicholas Galakatos
Nicholas Galakatos Director @ Praxis Precision Medicines
Director

steven-petrou_image

Steven Petrou
Steven Petrou Co-Founder, Chief Scientific Officer @ Praxis Precision Medicines
Co-Founder, Chief Scientific Officer
2022-04-01

Founder


david-goldstein_image

David Goldstein

kiran-reddy_image

Kiran Reddy

steven-petrou_image

Steven Petrou

Stock Details


Company's stock symbol is NASDAQ:PRAX

Investors List

ocv_image

OCV

OCV investment in Series C - Praxis Precision Medicines

eventide-asset-management_image

Eventide

Eventide investment in Series C - Praxis Precision Medicines

irving-investors_image

Irving Investors

Irving Investors investment in Series C - Praxis Precision Medicines

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - Praxis Precision Medicines

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series C - Praxis Precision Medicines

avoro-capital-advisors_image

Avoro Capital Advisors

Avoro Capital Advisors investment in Series C - Praxis Precision Medicines

blackstone-life-science_image

Blackstone Life Sciences

Blackstone Life Sciences investment in Series C - Praxis Precision Medicines

point72-ventures_image

Point72 Ventures

Point72 Ventures investment in Series C - Praxis Precision Medicines

surveyor-capital_image

Surveyor Capital

Surveyor Capital investment in Series C - Praxis Precision Medicines

qatar-investment-authority_image

Qatar Investment Authority

Qatar Investment Authority investment in Series C - Praxis Precision Medicines

Official Site Inspections

http://www.praxismedicines.com Semrush global rank: 2.22 M Semrush visits lastest month: 9.44 K

  • Host name: 172.67.215.221
  • IP address: 172.67.215.221
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Praxis Precision Medicines"

Corporate Governance - Praxis Precision Medicines, Inc.

The Board of Directors of Praxis Precision Medicines (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»

Press Release - investor.praxismedicines.com

May 23, 2022 For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter. Investor Contact: Alex Kane Praxis Precision Medicines …See details»

Praxis Precision Medicines Adds Neurology Expertise to Board of ...

Apr 29, 2021 Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale …See details»

Praxis Precision Medicines - Crunchbase Company …

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance.See details»

Praxis Precision Medicines, Inc. | LinkedIn

Praxis Precision Medicines, Inc. | 10,137 followers on LinkedIn. The era of genetic neuroscience has arrived | Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating ...See details»

Company Description - Stock Analysis

Oct 16, 2020 Ticker Symbol: PRAX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $19.00: CIK Code: 0001689548: CUSIP Number: …See details»

Quarterly Results - Praxis Precision Medicines, Inc.

The Investor Relations website contains information about Praxis Precision Medicines, Inc.'s business for stockholders, potential investors, and financial analysts.See details»

Press Release - Praxis Precision Medicines, Inc.

Jun 30, 2023 Investor Contact Praxis Precision Medicines [email protected] 857-702-9452 Media Contact Ian Stone Canale Communications [email protected] …See details»

Praxis Precision Medicines Announces Management Team

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...See details»

Press Release - Praxis Precision Medicines, Inc.

Dec 31, 2022 1 mADL is a composite sum of items 1 to 11 of the TETRAS-ADL subscale and items 6 (bilateral) and 7 of the TETRAS-PS; mADL score is calculated as the sum of all 13 …See details»

Praxis Precision Medicines Provides Update on Advancing Clinical …

Jan 8, 2024 Praxis Precision Medicines, Inc. Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds …See details»

Press Release - Praxis Precision Medicines, Inc.

Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale Communications [email protected] …See details»

Praxis Precision Medicines Launches with over $100 Million to …

May 4, 2020 For more information, please visit www.praxismedicines.com. Contacts. Alicia Davis, THRUST Strategic Communications [email protected] 910-620-3302 Release …See details»

Praxis Precision Medicines Adds Neurology Expertise to Board of ...

CONTACT: Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale …See details»

Press Release - Praxis Precision Medicines, Inc.

May 9, 2022 Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale …See details»

Press Release - Praxis Precision Medicines, Inc.

May 10, 2024 For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X. Investor Contact: Praxis Precision Medicines …See details»

Praxis Precision Medicines Adds Global Business Expertise to …

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the …See details»

Press Releases - Praxis Precision Medicines, Inc.

Sep 4, 2024 Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic …See details»

Praxis Precision Medicines Announces $110 Million Financing

Jul 28, 2020 We have established a broad portfolio, including five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain …See details»

linkstock.net © 2022. All rights reserved